Tianjin consortium develops endometrial regenerative cell therapy

A Tianjin-based consortium with Shunho Co as the lead company focused on endometrial regenerative cell (ERC) technology has been selected for a major national grant on drug development. ERC can be Isolated from placental tissue and developed in a range of personalized stem cell preparations.

China Bio news release, November 29, 2013

Tianjin consortium develops endometrial regenerative cell therapy
Scroll to top